VIDEO: Trial builds on current microsatellite instability-high colorectal cancer therapy
In this video, Arvind N. Dasari, MD, MS, discussed the results of the CheckMate 8HW trial in which nivolumab and ipilimumab were compared with nivolumab monotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer.
The randomized phase 3 trial compared dual checkpoint inhibition and showed improvement in median progression-free survival with a hazard ratio of 0.62, favoring nivolumab (Opdivo, Bristol Myers Squibb) plus ipilimumab (Yervoy, Bristol Myers Squibb).
“What was really compelling was that the responses that were noted were around 58% in the nivolumab arm and 71% in the nivolumab plus ipilimumab arm, which is statistically significant. The difference, the duration of response was very, very durable with regards to the tolerability of these regimens,” Dasari, an associate professor of medical oncology at The University of Texas MD Anderson Cancer Center, said.
Reference:
- Andre T, et al. Abstract LBA143. Presented at: ASCO Gastrointestinal Cancers Symposium; Jan. 23-25, 2025; San Francisco.
Collapse
Read more about